At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 41 enrolled
Drug / intervention
Ranibizumab 0.5 mg +1 moredrug
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration
In Brief
A Phase 4 clinical trial evaluating Ranibizumab 0.5 mg and Aflibercept 2 mg for Wet Age-Related Macular Degeneration. Completed, enrolled 41 participants across 6 sites.
Detailed Summary
The purpose of the study was to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in treatment naïve wet neovascular Age-related Macular Degeneration (wAMD) patients in a detailed time course.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWet Age-Related Macular Degeneration
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartApr 2015
Primary CompletionMar 2017
Study CompletionJun 2017
TodayJul 2026
First PostedOct 6, 2014
Enrollment StartApr 8, 2015
Primary CompletionMar 20, 2017
Study CompletionJun 8, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.7 years ago
Interventions
Ranibizumab 0.5 mgdrug
Administered as an intravitreal injection
Aflibercept 2 mgdrug
Administered as an intravitreal injection